Cooper Companies Reports 5.7% Revenue Growth in Q3 Fiscal 2025

The Cooper Companies, Inc. reported a notable increase in financial performance for the third quarter of fiscal 2025, with net sales reaching $1,060.3 million, up from $1,002.8 million in the same period last year, marking a growth of 5.7%. For the nine months ending July 31, 2025, net sales totaled $3,027.3 million, compared to $2,877.0 million in the prior year, reflecting an increase of 5.2%. The company's gross profit for the quarter was $692.0 million, up from $663.0 million, while net income decreased slightly to $98.3 million from $104.7 million year-over-year. Earnings per share for the quarter were $0.49, down from $0.53 in the previous year.

The financial results indicate a mixed performance compared to the previous fiscal period. While net sales and gross profit increased, net income and earnings per share saw declines. The decrease in net income was attributed to higher selling, general, and administrative expenses, which rose to $421.7 million from $381.1 million, driven by increased selling activities and long-lived asset write-offs related to a product line exit. Research and development expenses also increased to $44.6 million from $39.0 million, reflecting a focus on enhancing product offerings.

Strategically, Cooper Companies has made significant acquisitions to bolster its market position. Notably, CooperSurgical completed the acquisition of obp Surgical for $100 million, enhancing its portfolio in the surgical device market. Additionally, the company acquired a fertility company specializing in sperm separation devices for $33.5 million. These acquisitions are expected to contribute to future growth and operational synergies. The company also reported a strong performance in its CooperVision segment, with net sales increasing by 6% to $718.4 million, driven by the success of its Biofinity and MyDay product lines.

Operationally, Cooper Companies has seen an increase in customer engagement, with a focus on expanding its geographic footprint. The Americas and EMEA regions reported sales growth of 2% and 14%, respectively, attributed to market gains in silicone hydrogel contact lenses. The company’s total assets increased to $12,376.7 million from $12,315.2 million, with cash and cash equivalents rising to $124.9 million. The company also repurchased 1.2 million shares of its common stock during the nine months ended July 31, 2025, for $92.8 million, reflecting a commitment to returning value to shareholders.

Looking ahead, Cooper Companies remains optimistic about the long-term prospects for the contact lens and healthcare markets, despite facing challenges such as global economic uncertainties and regulatory changes. The company plans to continue leveraging its acquisitions and product innovations to drive growth, particularly in the specialty eye care and fertility markets. The management anticipates that ongoing investments in research and development will enhance its competitive position and support future revenue growth.